1. Lan YY, Kovinthapillai R, Kędzia A, Niechciał E. Age-based challenges to type 1 diabetes management in the pediatric population. Front Pediatr. 2024; 12: 1434276. https://doi:10.3389/fped.2024.1434276
2.
Rimon MTI, Hasan MW, Hassan MF, Cesmeci S. Advancements in insulin pumps: a comprehensive exploration of insulin pump systems, technologies, and future directions. Pharmaceutics. 2024; 16(7): 944. https://doi:10.3390/pharmaceutics16070944
3.
Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev. 2023; 44(2): 254-280. https://doi:10.1210/endrev/bnac022
4.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009; 32: S62-S67. https://doi:10.2337/dc09-S062
5.
International Diabetes Federation. IDF Diabetes Atlas (10th ed.). Brussels: International Diabetes Federation; 2021.
6.
Norris JM, Johnson RK, Stene LC. Type 1 diabetes—early life origins and changing epidemiology. The Lancet Diabetes & Endocrinology. 2020; 8(3): 226-238. https://doi.org/10.1016/S2213-8587(19)30412-7
7.
Chobot A, Polanska J, Deja G, Jarosz-Chobot P. Increasing trend of childhood type 1 diabetes incidence: 20-year nationwide study in Poland. Pediatric Diabetes. 2023; 24(5): 533-541. https://doi.org/10.1111/pedi.13461
8.
Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology. 2019; 15(11): 635-650. https://doi.org/10.1038/s41574-019-0254-y
9.
Sherr JL, Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, et al. ISPAD clinical practice consensus guidelines 2018: diabetes technologies. Pediatric Diabetes. 2018; 19(Suppl 27): 302-325. https://doi.org/10.1111/pedi.12731
10.
Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technology & Therapeutics. 2016; 18(9): 532-538. https://doi.org/10.1089/dia.2016.0171
11.
Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021; 64(5): 1007-1015. https://doi.org/10.1007/s00125-021-05391-w
12.
Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021; 64(5): 1007-1015. https://doi.org/10.1007/s00125-021-05391-w
13.
U.S. Federal Food and Drug Administration. FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system [Internet]. Silver Spring: FDA; 2019 Dec 13 [access 2025 March 3]. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-interoperable-automated-insulin-dosing-controller-designed-allow-more-choices
14.
U.S. Federal Food and Drug Administration. FDA approves automated insulin delivery and monitoring system for use in younger pediatric patients [Internet]. Silver Spring: FDA; 2018 Jun 21 [access 2025 March 3]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-automated-insulin-delivery-and-monitoring-system-use-younger-pediatric-patients
15.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71. https://doi:10.1136/bmj.n71
16.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 2019; 366: l4898. https://doi.org/10.1136/bmj.l4898
17.
Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019; 42(3): 400-405. https://doi.org/10.2337/dc18-1444
18.
Petrovski G, Al Khalaf F, Campbell J, Day E, Almajaly D, Hussain K, et al. Successful transitioning children and adolescents with type 1 diabetes from multiple daily injections to advanced hybrid closed-loop system in 10 days: a prospective intervention study on MiniMed 780G system. Acta Diabetologica. 2022; 59(5): 743-746. https://doi.org/10.1007/s00592-022-01851-w
19.
Castorani V, Rigamonti A, Frontino G, Morotti E, Sandullo F, Scialabba F, et al. Turning the tides: achieving rapid and safe glucose control in adolescents with suboptimally controlled type 1 diabetes using advanced hybrid closed loop systems. Frontiers in Endocrinology. 2024; 15: 1243565. https://doi.org/10.3389/fendo.2024.1243565
20.
Sherr JL, Buckingham BA, Forlenza GP, Galderisi A, Ekhlaspour L, Wadwa RP, et al. Safety and performance of the omnipod hybrid closed-loop system in adults, adolescents, and children with type 1 diabetes over 5 days under free-living conditions. Diabetes Technology & Therapeutics. 2020; 22(3): 174-184. https://doi.org/10.1089/dia.2019.0286
21.
Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, et al. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet. Digital health. 2022; 4(4): e245-e255. https://doi.org/10.1016/S2589-7500(22)00020-6
22.
Delgado AM, Lucas F. The Tandem Control-IQ advanced hybrid system improves glycemic control in children under 18 years of age with type 1 diabetes and night rest in caregivers. Endocrinologia, Diabetes y Nutricion. 2023; 70(Suppl. 3): 27-35. https://doi.org/10.1016/j.endien.2023.08.005
23.
Lendínez-Jurado A, López-Siguero JP, Gómez-Perea A, Ariza-Jiménez AB, Becerra-Paz I, Tapia-Ceballos L, et al. Pediatric type 1 diabetes: is age at onset a determining factor in advanced hybrid closed-loop insulin therapy?. Journal of Clinical Medicine. 2023; 12(21): 6951. https://doi.org/10.3390/jcm12216951
24.
Petrovski G, Al Khalaf F, Campbell J, Umer F, Almajaly D, Hamdan M, et al. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol. 2021; 58: 207-213. https://doi.org/10.1007/s00592-020-01607-4
25.
Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, et al. Improved glycemic outcomes with medtronic minimed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care. 2021; 44(4): 969-975. https://doi.org/10.2337/dc20-2250
26.
Lindkvist EB, Laugesen C, Reenberg AT, Ritschel TKS, Svensson J, Jørgensen JB, et al. Performance of a dual-hormone closed-loop system versus insulin-only closed-loop system in adolescents with type 1 diabetes. A single-blind, randomized, controlled, crossover trial. Frontiers in Endocrinology. 2023; 14: 1073388. https://doi.org/10.3389/fendo.2023.1073388
27.
Petrovski G, Al Khalaf F, Campbell J, Day E, Almajaly D, Hussain K et al. Glycemic outcomes of advanced hybrid closed loop system in children and adolescents with type 1 diabetes, previously treated with multiple daily injections (MiniMed 780G system in T1D individuals, previously treated with MDI). BMC Endocrine Disorders. 2022; 22(1): 80. https://doi.org/10.1186/s12902-022-00996-7
28.
Petrovski G, Campbell J, Pasha M, Hussain K, Khalifa A, Umer F, et al. Twelve-month follow-up from a randomized controlled trial of simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed™ 780G advanced hybrid closed-loop system. Diabetes Technology & Therapeutics. 2024; 26(S3): 76-83. https://doi.org/10.1089/dia.2023.0429
29.
Cherubini V, Rabbone I, Berioli MG, Giorda S, Lo Presti D, Maltoni G, et al. Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective, multicentre, real-life study. Diabetes, Obesity & Metabolism. 2021; 23(11): 2484-2491. https://doi.org/10.1111/dom.14491
30.
Pihoker C, Shulman DI, Forlenza GP, Kaiserman KB, Sherr JL, Thrasher JR, et al. MiniMed AHCL Study Group. Safety and glycemic outcomes during the MiniMedTM advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. Diabetes Technology & Therapeutics. 2023; 25(11): 755-764. https://doi.org/10.1089/dia.2023.0255
31.
Tinti D, Nobili C, Baretta I, Rosso A, Trada M, de Sanctis L. Paediatric type 1 diabetes mellitus: a comparison between multi-injection therapy and advanced hybrid closed-loop pump in the first year after diabetes onset. Diabetes, Obesity & Metabolism. 2024; 26(9): 4100-4104. https://doi.org/10.1111/dom.15704
32.
Cherubini V, Fargalli A, Arnaldi C, Bassi M, Bonfanti R, Patrizia Bracciolini G, et al. Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: a multicenter real-world observational study. Diabetes Research and Clinical Practice. 2024; 210: 111621. https://doi.org/10.1016/j.diabres.2024.111621
33.
Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, Thankamony A, et al. Randomized trial of closed-loop control in very young children with type 1 diabetes. The New England Journal of Medicine. 2022; 386(3): 209-219. https://doi.org/10.1056/NEJMoa2111673
34.
Lendínez-Jurado A, Gómez-Perea A, Ariza-Jiménez AB, Tapia-Ceballos L, Becerra-Paz I, Martos-Lirio MF, et al. Impact on glucometric variables and quality of life of the advanced hybrid closed-loop system in pediatric and adolescent type 1 diabetes. Journal of Diabetes. 2023; 15(8): 699-708. https://doi.org/10.1111/1753-0407.13426
35.
Santova A, Plachy L, Neuman V, Pavlikova M, Petruzelkova L, Konecna P, et al. Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study. Frontiers in Endocrinology. 2023; 14: 1283181. https://doi.org/10.3389/fendo.2023.1283181
36.
Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, et al. A randomized trial of closed-loop control in children with type 1 diabetes. The New England Journal of Medicine. 2022; 383(9): 836-845. https://doi.org/10.1056/NEJMoa2004736
37.
Wadwa RP, Reed ZW, Buckingham BA, DeBoer MD, Ekhlaspour L, Forlenza GP, et al. PEDAP Trial Study Group. Trial of hybrid closed-loop control in young children with type 1 diabetes. The New England Journal of Medicine. 2023; 388(11): 991-1001. https://doi.org/10.1056/NEJMoa2210834
38.
Gianini A, Suklan J, Skela-Savič B, Klemencic S, Battelino T, Dovc K, et al. Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery. Frontiers in Endocrinology. 2022; 13: 967725. https://doi.org/10.3389/fendo.2022.967725
39.
Ng SM, Katkat N, Day H, Hubbard R, Quinn M, Finnigan L. Real-world prospective observational single-centre study: hybrid closed loop improves HbA1c, time-in-range and quality of life for children, young people and their carers. Diabetic Medicine: a Journal of the British Diabetic Association. 2022; 39(7): e14863. https://doi.org/10.1111/dme.14863
40.
Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, et al. A pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications. 2022; 13(1): 4940. https://doi.org/10.1038/s41467-022-32289-x
41.
Ware J, Allen JM, Boughton CK, Cezar A, Hartnell S, Wilinska ME, et al. Hybrid closed-loop with faster insulin aspart compared with standard insulin aspart in very young children with type 1 diabetes: a double-blind, multicenter, randomized, crossover study. Diabetes Technology & Therapeutics. 2023; 25(6): 431-436. https://doi.org/10.1089/dia.2023.0042
42.
Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, Allen JM, et al. Young children have higher variability of insulin requirements: observations during hybrid closed-loop insulin delivery. Diabetes Care. 2019; 42(7): 1344-1347. https://doi.org/10.2337/dc18-2625
43.
Tauschmann M, Allen JM, Nagl K, Fritsch M, Yong J, Metcalfe E, et al. Home use of day-and-night hybrid closed-loop insulin delivery in very young children: a multicenter, 3-week, randomized trial. Diabetes Care. 2019; 42(4): 594-600. https://doi.org/10.2337/dc18-1881
44.
Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, et al. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes, Obesity & Metabolism. 2021; 23(9): 2048-2057. https://doi.org/10.1111/dom.14441
45.
Petruzelkova L, Jiranova P, Soupal J, Kozak M, Plachy L, Neuman V, et al. Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: a retrospective analysis. Pediatric Diabetes. 2021; 22(4): 594-604. https://doi.org/10.1111/pedi.13190
46.
Tornese G, Buzzurro F, Carletti C, Faleschini E, Barbi E. Six-month effectiveness of advanced vs. standard hybrid closed-loop system in children and adolescents with type 1 diabetes mellitus. Frontiers in Endocrinology. 2021; 12: 766314. https://doi.org/10.3389/fendo.2021.766314
47.
Varimo T, Pulkkinen MA, Hakonen E, Hero M, Miettinen PJ, Tuomaala AK. First year on commercial hybrid closed-loop system-experience on 111 children and adolescents with type 1 diabetes. Pediatric Diabetes. 2021; 22(6): 909-915. https://doi.org/10.1111/pedi.13235
48.
Bombaci B, Passanisi S, Alibrandi A, D'Arrigo G, Patroniti S, Averna S, et al. One-year real-world study on comparison among different continuous subcutaneous insulin infusion devices for the management of pediatric patients with type 1 diabetes: the supremacy of hybrid closed-loop systems. International Journal of Environmental Research and Public Health. 2022; 19(16): 10293. https://doi.org/10.3390/ijerph191610293
49.
Forlenza GP, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, Shulman DI, et al. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial. Pediatric Diabetes. 2022; 23(3): 324-329. https://doi.org/10.1111/pedi.13312
50.
Kariyawasam D, Morin C, Casteels K, Le Tallec C, Sfez A, Godot C, et al. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial. The Lancet. Digital Health. 2022; 4(3): e158-e168. https://doi.org/10.1016/S2589-7500(21)00271-5
51.
Schiaffini R, Deodati A, Nicoletti MC, Carducci C, Ciampalini P, Lorubbio A, et al. Comparison of two advanced hybrid closed loop in a pediatric population with type 1 diabetes: a real-life observational study. Acta Diabetologica. 2022; 59(7): 959-964. https://doi.org/10.1007/s00592-022-01886-z
52.
Seget S, Jarosz-Chobot P, Ochab A, Polanska J, Rusak E, Witoszek P, et al. Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stable – 1-year prospective, observational, two-center study. Frontiers in Endocrinology. 2022; 13: 1036808. https://doi.org/10.3389/fendo.2022.1036808
53.
Vijayanand S, Stevenson PG, Broad E, Davis EA, Taplin CE, Jones TW, et al. Evaluation of real-life clinical outcomes in Australian youth with type 1 diabetes on hybrid closed-loop therapy: a retrospective study. Journal of Paediatrics and Child Health. 2022; 58(9): 1578-1583. https://doi.org/10.1111/jpc.16043
54.
von dem Berge T, Remus K, Biester S, Reschke F, Klusmeier B, Adolph K, et al. In-home use of a hybrid closed loop achieves time-in-range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial. Diabetes, Obesity & Metabolism. 2022; 24(7): 1319-1327. https://doi.org/10.1111/dom.14706
55.
Cordero TL, Dai Z, Arrieta A, Niu F, Vella M, Shin J, et al. Glycemic outcomes during early use of the MiniMed™ 780G advanced hybrid closed-loop system with Guardian™ 4 Sensor. Diabetes Technology & Therapeutics. 2023; 25(9): 652-658. https://doi.org/10.1089/dia.2023.0123
56.
Coutant R, Bismuth E, Bonnemaison E, Dalla-Vale F, Morinais P, Perrard M, et al. Hybrid closed loop overcomes the impact of missed or suboptimal meal boluses on glucose control in children with type 1 diabetes compared to sensor-augmented pump therapy. Diabetes Technology & Therapeutics. 2023; 25(6): 395-403. https://doi.org/10.1089/dia.2022.0518
57.
Elbarbary NS, Ismail EAR. MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users. Diabetology & Metabolic Syndrome; 2023; 15(1): 205. https://doi.org/10.1186/s13098-023-01184-w
58.
Piccini B, Felicioni M, Pessina B, Bertini M, Casalini E, Ceccotti C, et al. Glycemic control, basal/bolus distribution, BMI and Meal management in children and adolescents with type 1 diabetes and advanced hybrid closed loop. Nutrients. 2023; 15(23): 4875. https://doi.org/10.3390/nu15234875
59.
Tornese G, Carletti C, Lanzetta MA, Tamaro G, Barbi E, Faleschini E. Safety of real-life usage of advanced hybrid closed-loop system MiniMed 780G in children with type 1 diabetes younger than 7 years old. Diabetes Care. 2023; 46(6): e123-e125. https://doi.org/10.2337/dc22-2046
60.
Martin-Payo R, Fernandez-Alvarez MDM, García-García R, Pérez-Varela Á, Surendran S, Riaño-Galán I. Effectiveness of a hybrid closed-loop system for children and adolescents with type 1 diabetes during physical exercise: a cross-sectional study in real life. Anales de Pediatria. 2024; 101(3): 183-189. https://doi.org/10.1016/j.anpede.2024.07.015
61.
Seget S, Chobot A, Tarasiewicz M, Bielawska A, Rusak E, Ochab A, et al. Glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center study. Frontiers in Endocrinology. 2024; 15: 1332418. https://doi.org/10.3389/fendo.2024.1332418
62.
Rapini N, Martino M, Arnaldi C, Deodati A, Anagnostopoulou L, Amodeo ME, et al. Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years. Frontiers in Endocrinology. 2024; 15: 1382920. https://doi.org/10.3389/fendo.2024.1382920
Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
